Last updated: 03/05/2025 08:40:17
Special Drug Use Investigation for ReQuip® Controlled-Release (CR)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Special Drug Use Investigation for ReQuip® Controlled-Release (CR)
Trial description: This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data for long-term use among subjects with parkinson's disease who are treated with ropinirole tablets for the first time.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Occurrence of adverse events of sudden onset of sleep
Timeframe: 1 year
Occurrence of adverse events of somnolence
Timeframe: 1 year
Changes in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) scores
Timeframe: 1 year
Occurrence of adverse drug reactions under clinical practice
Timeframe: 1 year
Occurrence of adverse events of psychiatric symptom such as hallucination, delusion, agitation, confusional state and delirium
Timeframe: 1 year
Secondary outcomes:
Not applicable
Interventions:
Drug: Ropinirole tablets
Enrollment:
667
Observational study model:
Cohort
Primary completion date:
2015-21-10
Time perspective:
Prospective
Clinical publications:
Kazuko Hasegawa, Atsuko Ishida, Masao Yarita, Terufumi Hara. Assessment of Safety and Effectiveness of Ropinirole Hydrochloride Controlled-Release Tablets in Parkinson's Disease Patients in Long-Term Dairy Clinical Practice. -Report of Special Drug Use Investigation. Prog Med. 2016;36(6):97-100
Medical condition
Parkinson Disease
Product
ropinirole
Collaborators
Not applicable
Study date(s)
October 2012 to October 2015
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
none
- Patients with Parkinson's disease
- Patients who are treated with ropinirole tablets for the first time
- None
Inclusion and exclusion criteria
Inclusion criteria:
- Patients with Parkinson's disease
- Patients who are treated with ropinirole tablets for the first time
- Patients who are expected for long-term use (1 year)
Exclusion criteria:
- None
Trial location(s)
No location data available.
Study documents
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2015-21-10
Actual study completion date
2015-21-10
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website